Aurinia Pharmaceuticals (AUPH) vs Prestige Consumer Healthcare (PBH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aurinia Pharmaceuticals (AUPH) has outperformed Prestige Consumer Healthcare (PBH) over the past year, gaining 40.7% versus a loss of 24.4%. Over five years, PBH leads with a -18.1% price change compared with -21.1% for AUPH. Prestige Consumer Healthcare is the larger company by market cap ($2.28 billion vs $2.22 billion), about 1.0 times the size, while Aurinia Pharmaceuticals is growing revenue faster (+20.4% vs -4.3%).
On valuation, Prestige Consumer Healthcare trades at a lower forward P/E (9.5x vs 15.6x for Aurinia Pharmaceuticals). Aurinia Pharmaceuticals converts more of its revenue into profit, with a net margin of 101.5% versus 17.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | PBH |
|---|---|---|
| Share price | $16.65 | $48.23 |
| Market cap | $2.22B | $2.28B |
| 1-day change | +2.65% | +0.75% |
| YTD return | +1.69% | -22.40% |
| 1-year return | +40.68% | -24.36% |
| 5-year return | -21.15% | -18.06% |
| P/E ratio (TTM) | 7.30 | 13.51 |
| Forward P/E | 15.61 | 9.49 |
| EPS (TTM) | $2.28 | $3.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $283.06M | $1.09B |
| Revenue growth (YoY) | +20.38% | -4.31% |
| Net income (latest FY) | $287.20M | $190.30M |
| Gross margin | 88.46% | 54.71% |
| Operating margin | 37.06% | 28.42% |
| Net margin | 101.47% | 17.48% |
| 52-week high | $19.25 | $71.07 |
| 52-week low | $10.90 | $42.62 |
| Distance from 52-week high | -13.51% | -32.14% |
| Analyst consensus | none | buy |
| Avg. price target upside | +7.27% | +40.58% |
| Average volume | 977.05K | 547.31K |
| Shares outstanding | 133.05M | 47.37M |
| Employees | 128 | 890 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AUPH has outperformed PBH by 65.0 percentage points over the past year.
- Prestige Consumer Healthcare trades at a higher earnings multiple (13.5x vs 7.3x trailing P/E).
- Aurinia Pharmaceuticals is more profitable, keeping 101.5 cents of every revenue dollar as net income versus 17.5 cents for Prestige Consumer Healthcare.
- Aurinia Pharmaceuticals grew revenue faster in its latest fiscal year (+20.38% vs -4.31%).
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Prestige Consumer Healthcare
PBH stock →Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Health Care · Biotechnology: Pharmaceutical Preparations · 890 employees
AUPH vs PBH FAQ
Which is bigger, Aurinia Pharmaceuticals or Prestige Consumer Healthcare?
Prestige Consumer Healthcare (PBH) is larger, with a market capitalization of $2.28B compared with $2.22B for Aurinia Pharmaceuticals (AUPH).
Which stock has performed better over the past year, AUPH or PBH?
AUPH returned +40.68% over the past 12 months, compared with -24.36% for PBH (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AUPH or PBH?
AUPH has the lower trailing P/E at 7.3, versus 13.5 for PBH. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Aurinia Pharmaceuticals and Prestige Consumer Healthcare in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.